非酒精性脂肪性肝病与非酒精性脂肪性肝炎的当前及未来治疗方案
非酒精性脂肪性肝病(NAFLD)及其进展型非酒精性脂肪性肝炎(NASH)正迅速成为肝硬化、肝细胞癌和肝移植指征的主要原因之一。除通过饮食和运动改变生活方式外,目前尚无其他获批的NASH/NAFLD治疗方法。减重可能有效但难以实现和维持,而减重手术可改善NAFLD相关的代谢状况并已被显示可改善肝脏组织学。要使NASH/NAFLD治疗方案获得批准,必须解决若干问题。首先,所有利益相关方必须就NASH最合适的临床试验终点达成一致。目前,监管机构接受的终点是NASH缓解(不伴纤维化恶化)或纤维化分期降低(不伴NASH恶化)。认识NASH组织学特征的预后意义很重要。在此背景下,尽管组织学NASH与晚期纤维化相关,但它并非长期死亡率的独立预测因子。相反,有大量数据提示纤维化分期是肝脏相关死亡率唯一稳健且独立的预测因子。除主要终点外,还必须考虑若干重要的次要终点,包括无创生物标志物、长期结局和患者报告结局。2018年,一些治疗NASH的3期临床试验已经启动。此外,针对NASH不同致病通路的多项2a期和2b期临床试验正在新兴疗法的研发管线中。结论:在未来5年内,其中一些方案有望为NASH/NAFLD患者提供潜在的新治疗选择。(Hepatology 2018;68:361-371)
要点
- 除饮食和运动改变生活方式外,目前尚无其他获批的NASH/NAFLD治疗方法。
- 监管机构接受的NASH试验主要终点为NASH缓解(不伴纤维化恶化)或纤维化分期降低(不伴NASH恶化)。
- 纤维化分期是肝脏相关死亡率唯一稳健且独立的预测因子,而组织学NASH并非长期死亡率的独立预测因子。
核心结论
- 在未来5年内,一些在研方案有望为NASH/NAFLD患者提供潜在的新治疗选择。
研究设计与样本
- 本文为综述,总结NAFLD/NASH当前及未来治疗方案、临床试验终点与在研药物管线。
主要发现
- 除饮食和运动改变生活方式外,目前尚无其他获批的NASH/NAFLD治疗方法。
- 减重可能有效但难以实现和维持;减重手术可改善NAFLD相关代谢状况,并已被显示可改善肝脏组织学。
- 组织学NASH与晚期纤维化相关,但并非长期死亡率的独立预测因子;纤维化分期是肝脏相关死亡率唯一稳健且独立的预测因子。
- 2018年已启动一些治疗NASH的3期临床试验,针对不同致病通路的多项2a期和2b期临床试验正在研发管线中。
关键数值与推荐
- 监管机构接受的NASH试验主要终点为NASH缓解(不伴纤维化恶化)或纤维化分期降低(不伴NASH恶化)。
- 次要终点须考虑无创生物标志物、长期结局和患者报告结局。
临床怎么用
- 生活方式改变(饮食和运动)仍是目前NASH/NAFLD的基础治疗;减重手术可改善代谢状况及肝脏组织学。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) and its progressive form non-alcoholic steatohepatitis (NASH), are rapidly becoming among the top causes of cirrhosis, hepatocellular carcinoma, and indications for liver transplantation. Other than lifestyle modification through diet and exercise, there are currently no other approved treatments for NASH/NAFLD. Although weight loss can be effective, it is difficult to achieve and sustain. In contrast, bariatric surgery can improve metabolic conditions associated with NAFLD, and has been shown to improve liver histology. To have approved regimens for the treatment of NASH/NAFLD, several issues must be addressed. First, all stakeholders must agree on the most appropriate clinical trial endpoints for NASH. Currently, resolution of NASH (without worsening fibrosis) or reduction of fibrosis stage (without worsening NASH) are the accepted endpoints by the regulatory authorities. It is important to recognize the prognostic implication of histologic features of NASH. In this context, although histologic NASH has been associated with advanced fibrosis, it is not an independent predictor of long-term mortality. In contrast, there are significant data to suggest that fibrosis stage is the only robust and independent predictor of liver-related mortality. In addition to the primary endpoints, several important secondary endpoints, including noninvasive biomarkers, long-term outcomes, and patient-reported outcomes must be considered. In 2018, a few phase 3 clinical trials for the treatment of NASH have been initiated. Additionally, a number of phase 2a and 2b clinical trials targeting different pathogenic pathways in NASH are in the pipeline of emerging therapies. CONCLUSION: Over the next 5 years, some of these regimens are expected to provide potential new treatment options for patients with NASH/NAFLD. (Hepatology 2018;68:361-371).
引用
- Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018. PMID: 29222911. doi:10.1002/hep.29724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。